Idarubicin Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5 mg/5 mL
Reference Brands: Idamycin (USA)
Category:
Oncology Cancer Care
Idarubicin Hydrochloride is available in Injection
and strengths such as 5 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Idarubicin Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Idarubicin Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Idarubicin hydrochloride is an anthracycline antileukemic agent widely used in combination chemotherapy regimens for the treatment of acute myeloid leukemia (AML) in adult patients. It is commonly administered alongside other anticancer drugs during induction therapy under strict oncologist supervision. In addition to its approved use in AML, idarubicin hydrochloride is also being studied for its potential role in the treatment of other malignancies.
Pharmacologically, idarubicin hydrochloride works by intercalating into DNA and inhibiting the activity of topoisomerase II, an essential enzyme involved in DNA replication, transcription, and repair. By blocking this enzyme, the drug prevents proper DNA unwinding and cell division, ultimately leading to cancer cell death. The compound is a structural analog of daunorubicin; however, the absence of a methoxy group increases its lipophilicity, allowing for enhanced cellular uptake and greater antitumor activity.
Like other anthracyclines, idarubicin hydrochloride also affects chromatin structure by inducing histone eviction, further disrupting cancer cell survival mechanisms. Due to its potent cytotoxic effects, its use requires careful dosing and monitoring in specialized oncology settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing